John Bencich - 04 Mar 2024 Form 4 Insider Report for ACHIEVE LIFE SCIENCES, INC. (ACHV)

Reporting relationship: CEO, Director
Issuer ticker: ACHV
Reported as of: 04 Mar 2024
Net transaction value: +$45,850
SEC form: 4
Accepted by SEC: 06 Mar 2024, 16:43:53 UTC
Prior SEC filing: 24 Jan 2024
Next SEC filing: 23 Apr 2024
Source filing: View source filing
Reporting owner signature: Sandra Thomson as attorney-in-fact for John Bencich

Key filing fact

John Bencich filed Form 4 for ACHIEVE LIFE SCIENCES, INC. (ACHV) on 06 Mar 2024.

Key facts

This page summarizes John Bencich's Form 4 filing for ACHIEVE LIFE SCIENCES, INC. (ACHV).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Mar 2024, 16:43.

Change

Previous filing in this sequence was filed on 24 Jan 2024.
Current net transaction value: +$45,850.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACHV transaction

Common Stock

Purchase

Transaction value: $45,850
Shares: +10,000
Change %: +15%
Price: $4.58
Shares after: 76,724
Date: 04 Mar 2024
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACHV transaction Derivative

Common Stock Warrants (right to buy)

Purchase

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 04 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $4.91
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The common shares reported on this Form 4 were purchased in a registered direct offering (the "RDO") at a price of $4.585, for an aggregate purchase price of $45,850 pursuant to a Securities Purchase Agreement (the "SPA") dated February 28, 2024. The SPA also provides for a concurrent private placement of warrants to purchase common shares (the "Private Placement Warrants") . The Private Placement Warrants are exercisable immediately upon issuance until the earlier of (x) three and one-half years after the date of issuance, and (y) 30 days following the Issuer's public disclosure of the acceptance of an NDA for cytisinicline by the FDA in a Day 74 Letter or equivalent correspondence.

Footnote F2

This number reflects a decrease of ownership of 6 shares of common stock from the number of shares previously reported due to an administrative error at the time of the Issuer's 1-for-20 split on July 31, 2020.